Orasis is an emerging ophthalmic pharmaceutical company with the goal of making near vision clear again. They are committed to the Ophthalmology and Optometry segments because they know that presbyopia is ubiquitous. By virtue of their first in class formulation, Orasis is well-positioned to be first-line therapy in this emerging category by addressing a significant unmet need for patients.

Pharmaceutical

Orasis Pharmaceuticals

Elad Kedar

Yaron Shimon

Merav Zeide

Ilan Rubin

Paul Smith

Iris Meisner

Ron Neumann

Sharon Amzel-Sasson

The leadership team at Orasis Pharmaceuticals has a long history of experience in the pharmaceutical industry, with members coming from a variety of companies such as Mediline LTD, PharmaSwiss, Eli Lilly, Teva Pharmaceuticals, Novartis, and TearLab Corporation. They also have a wide range of educational backgrounds, including degrees in accounting, law, economics, business management, finance, information systems, marketing, and advertising from Tel Aviv University, the University of Florida, and the University of Central Florida. Additionally, several members of the team have experience in ocular drug development and medical affairs.

Leadership Team

Board of Directors

CEO and Executive Team

Leadership Team

About

Team members

Other teams at Orasis Pharmaceuticals

Board of Directors

CEO and Executive Team